Biosyent (RX) AI Stock Analysis

• Market Cap: C$147.69M
• Dividend Yield: 1.6%
• Average Volume (3M): 5.67K
• Price to Earnings (P/E): 16.8
• Beta (1Y): 0.63
• Revenue Growth: 22.22%
• EPS Growth: 25.50%
• Country: CA
• Employees: 60
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.23
• Shares Outstanding: 11,475,447
• 10 Day Avg. Volume: 6,048
• 30 Day Avg. Volume: 5,666
• PEG Ratio: 1.05
• Price to Book (P/B): 3.64
• Price to Sales (P/S): 3.64
• P/FCF Ratio: 31.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$13.50
• Price Target Upside: 4.90% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 76 Outperform
• Price Target: C$14.00 ▲(8.78% Upside)

Biosyent's overall stock score is driven by strong financial performance and positive technical indicators. The company's robust revenue growth and profitability, combined with a positive market trend, support a favorable outlook. However, valuation metrics suggest the stock is fairly priced, and potential overbought conditions warrant caution.

Positive Factors

Revenue Growth

Biosyent's consistent revenue growth indicates a strong market position and effective product adoption, supporting long-term business expansion.

Balance Sheet Health

A low debt-to-equity ratio suggests minimal financial risk, providing Biosyent with greater stability and flexibility for future investments.

Profitability

Strong EBIT and EBITDA margins demonstrate operational efficiency and profitability, enhancing the company's ability to reinvest in growth opportunities.

Negative Factors

Gross Profit Margin Decline

A declining gross profit margin may indicate rising costs or pricing pressures, which could impact future profitability if not addressed.

Free Cash Flow Conversion

Suboptimal free cash flow conversion may limit Biosyent's ability to fund new projects or return capital to shareholders, affecting long-term growth.

Equity Ratio Decline

A declining equity ratio might indicate reduced financial resilience, potentially affecting the company's ability to withstand economic downturns.

Biosyent Business Overview & Revenue Model

Company Description

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

How the Company Makes Money

Biosyent generates revenue primarily through the sale of its prescription products to healthcare providers, hospitals, and pharmacies. The company operates a revenue model based on direct sales and partnerships with other pharmaceutical companies for the distribution of their products. Key revenue streams include the sale of proprietary drugs, royalties from licensed products, and potential milestones from collaboration agreements. Strategic partnerships with healthcare professionals and institutions also contribute to its earnings, as they help in expanding market reach and enhancing product visibility.

Biosyent Financial Statement Overview

Summary

Biosyent demonstrates strong financial health with consistent profitability, low leverage, and improving cash flows. The company maintains a solid financial position with a low debt-to-equity ratio and strong return on equity. However, slight declines in gross profit margin and free cash flow to net income ratio suggest potential cost pressures and reinvestment needs.

Income Statement

Biosyent's income statement shows strong profitability with a consistent gross profit margin above 78% and a net profit margin around 20%. The company has demonstrated positive revenue growth, particularly in the TTM period with a 3.23% increase. EBIT and EBITDA margins are robust, indicating efficient operations. However, the slight decline in gross profit margin over the years suggests potential cost pressures.

Balance Sheet

The balance sheet reflects a solid financial position with a low debt-to-equity ratio of 0.027 in the TTM period, indicating minimal leverage. Return on equity is strong at 21.76%, showcasing effective use of equity to generate profits. The equity ratio remains stable, highlighting a well-capitalized structure. The gradual decrease in debt-to-equity over the years is a positive trend.

Cash Flow

Cash flow analysis reveals significant improvement in free cash flow growth, particularly in the TTM period with a 232.55% increase. The operating cash flow to net income ratio is healthy, indicating strong cash generation relative to profits. However, the free cash flow to net income ratio has decreased, suggesting potential reinvestment or increased capital expenditures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	42.18M	35.03M	31.59M	27.93M	28.62M	22.33M
Gross Profit	32.67M	27.86M	25.60M	22.86M	22.64M	17.42M
EBITDA	12.72M	10.43M	9.06M	7.43M	8.64M	5.54M
Net Income	8.63M	7.27M	6.46M	5.46M	6.28M	3.80M
Balance Sheet
Total Assets	47.79M	41.36M	41.53M	40.49M	37.17M	33.57M
Cash, Cash Equivalents and Short-Term Investments	23.40M	15.94M	26.19M	28.70M	28.21M	25.58M
Total Debt	892.88K	1.04M	1.22M	1.40M	1.56M	1.71M
Total Liabilities	7.88M	6.36M	6.77M	7.12M	5.61M	6.78M
Stockholders Equity	39.90M	35.00M	34.76M	33.36M	31.55M	26.80M
Cash Flow
Free Cash Flow	7.76M	3.99M	4.88M	4.43M	4.58M	6.72M
Operating Cash Flow	8.14M	8.66M	5.05M	4.95M	4.67M	6.89M
Investing Cash Flow	2.59M	3.29M	883.85K	-10.79M	-4.84M	3.39M
Financing Cash Flow	-6.97M	-7.83M	-5.78M	-4.37M	-2.08M	-3.37M

Biosyent Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.87
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RX, the sentiment is Positive. The current price of 12.87 is above the 20-day moving average (MA) of 12.39, above the 50-day MA of 11.66, and above the 200-day MA of 11.41, indicating a bullish trend. The MACD of 0.30 indicates Positive momentum. The RSI at 65.96 is Neutral, neither overbought nor oversold. The STOCH value of 45.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:RX.

Biosyent Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RX	76 Outperform	C$147.69M	16.79	22.35%	1.60%	22.22%	25.50%
MDP	58 Neutral	C$97.26M	138.89	0.87%	―	2.14%	-83.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATLE	50 Neutral	C$58.12M	-2.88	-19.76%	―	26.91%	81.01%
HLS	48 Neutral	C$150.43M	-7.70	-20.49%	―	0.73%	33.51%
CRDL	47 Neutral	C$140.00M	-3.34	-341.20%	―	―	21.17%
AQS	38 Underperform	C$663.17K	-2.04	―	―	122.30%	75.74%

Biosyent Corporate Events

BioSyent Renews Share Repurchase Program to Enhance Shareholder Value

BioSyent Inc. has announced the renewal of its Normal Course Issuer Bid (NCIB), allowing the company to repurchase up to 800,000 of its common shares over a 12-month period, representing approximately 7.1% of its outstanding shares. The company believes that its shares may be undervalued and that repurchasing them is a strategic use of corporate funds, potentially benefiting remaining shareholders. The NCIB will be conducted through the TSX Venture Exchange or alternative Canadian trading systems, with purchases funded from the company’s cash reserves.

The most recent analyst rating on (TSE:RX) stock is a Buy with a C$13.50 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.

BioSyent Reports Strong Financial Growth in Q3 and YTD 2025

BioSyent Inc. reported significant financial growth in Q3 and YTD 2025, with total company sales increasing by 28% and 27% respectively. The company experienced strong performance across its Canadian and international pharmaceutical sales, as well as its legacy business. Despite some gross margin compression, BioSyent maintained a consistent EBITDA margin due to proportional operating expenses. The company continues to see profitable sales growth from its FeraMAX® and Tibella®/Tibelia® products, aligning with its strategic focus on sustained growth into 2026.

The most recent analyst rating on (TSE:RX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.

BioSyent to Announce Q3 and YTD 2025 Financial Results on November 20

BioSyent Inc. has scheduled the release of its financial results for the third quarter and year-to-date 2025 on November 20, 2025, after market hours. The announcement will include a presentation by the company’s President and CEO, René Goehrum, which will be available on the company’s website. This release is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (TSE:RX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.